To the best of our knowledge, this is the first study that suggested saroglitazar may exert its beneficial effects on hepatic steatosis through modulating leptin and adiponectin levels in the model of NASH. This evidence concerns the gene LEP and metabolic dysfunction-associated steatohepatitis.